Havn Life Archives - Green Market Report

StaffDecember 9, 2020
psychedelic.jpg?fit=960%2C640&ssl=1

5min10220

Mydecine Innovations

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) announced that it has completed its first commercial harvest of 20 kilograms of psilocybin mushrooms at its research and cultivation facility in Jamaica. The company said it is now preparing to export the harvest to its Canadian cGMP Facility which has a Health Canada schedule 1 Dealer’s License attached to it, allowing for legal import.

“We are pleased to announce the completion of our first commercial harvest of natural psilocybin mushrooms,” said Joshua Bartch, CEO and Chairman of Mydecine. “There is more research needed on these compounds in order to better understand the entourage effect experienced by patients which has shown dramatically effective results compared to single-molecule synthetic psilocybin in preliminary studies. As the industry grows, the need for naturally occurring psilocybin and access to large quantities of these molecules will be paramount and we are excited to be the first to advance this movement at scale.”

Mydecine said that its final product will be made available for purchase by other licensed institutions and companies conducting clinical research into the efficacy of these compounds to treat various health conditions including anxiety, addiction, depression and PTSD. Portions of the harvest will also be used for Mydecine’s proprietary genetic, pharmacology, and clinical research. The clinical use will be for the studies and developing protocols of psilocybin-assisted psychotherapy to treat PTSD in veterans and other frontline workers.

MindMed

Mind Medicine Inc. (NEO: MMED) (OTCQB: MMEDF) has filed a final short form prospectus with the securities commissions or similar authorities in each province of Canada, other than Québec with regards to a previously announced bought deal. The company’s underwriters have agreed to purchase 15,800,000 units of MindMed, on a “bought deal” basis, at a price per Unit of $1.90 for gross proceeds of $30,020,000.

The company said it has also granted the Underwriters an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional $4,503,000 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be $34,523,000.The Offering is scheduled to close on or about December 11, 2020.

Havn Life

Havn Life Sciences Inc. (CSE:HAVN)  has signed a Memorandum of Agreement with the international veteran’s organization, Heroic Hearts Project. Heroic Hearts is a registered 501(c)(3) nonprofit organization founded in the United States that connects military veterans struggling with mental trauma, to psychedelic therapy options including ayahuasca, psilocybin, and ketamine. Heroic Hearts also provides support and professional counseling to these veterans throughout the process. These veterans typically have tried all the available resources offered by the Department of Veteran Affairs with limited success leaving them with very few options. Heroic Hearts currently has branches across the United States, Canada, and the United Kingdom.

“This collaboration between Havn Life and Heroic Hearts has the potential to make an extraordinary impact on the mental health and wellness of military veterans,” said Susan Chapelle, EVP of Research and Development at Havn Life. “Under the agreement, Havn Life will supply products and compounds to be used in Heroic Hearts’ future clinical studies that will investigate the effects of low-dosage psychedelic compounds on veterans suffering from emotional trauma and PTSD. This progressive research will help develop clinical trial formulations to aid in the recovery of PTSD and other trauma-related disorders. We look forward to working closely with veterans and others with military backgrounds.”


Julie AitchesonJuly 6, 2020
Havn.jpg?fit=960%2C539&ssl=1

5min21240

Medical cannabis legalization is a fait accompli in thirty-three states and counting and eleven states have legalized recreational marijuana, suggesting a brighter horizon for other restricted plant medicines as well. Enter psychedelic mushrooms, otherwise known as Psilocybe spp., and Susan Chapelle, co-CEO of the newly-launched Havn Life, a company dedicated to developing a range of standardized, quality-controlled psilocybin products to be used by researchers.

Chapelle (whose bio includes being the first female steel rigger in North America, a two-time elected politician, and boasts years spent lobbying for health policy change), launched Havn Life as part of a larger mission to build evidence-informed natural healthcare products that help people manage their own healthcare. 

Developing a reliable, safe, standardized supply of psilocybin, which does not currently exist, is a central part of this broader vision. “A concern that all companies must grapple with as we look to the future of psychedelic medicines is the future of the supply chain,” Chappelle explains. “Havn Life is developing two labs in the South Campus of The University of British Columbia (UBC), where we will develop methodology for growing and extracting Psilocybe spp. These compounds will be available to academics studying psychedelics until policy becomes informed by evidence, and the market opens up to these compounds as approved medication.” But Susan Chapelle and her team do not intend to stop there, she states. “Havn Life is diversified and looking at other psychoactive compounds for use in Natural Health products to get to market using evidence-informed formulations derived from fungus and plants.”

Havn Life’s supply development won’t only benefit their own bottom line, however. “Havn Life is developing a reliable and safe supply chain of psychedelic compounds,” Chapelle says, “an essential component that will enable other companies to move to human clinical trials.” When I asked about the ways in which Havn Life is navigating the regulatory landscape as part of this endeavor, Chapelle informed me that “psilocybin is currently scheduled as a restricted compound by most governments. It is a controlled compound in Canada; however, both animal and human trials can be conducted through an application process to Health Canada. There is still a hangover effect from the ‘war on drugs,’ but ultimately the regulators must absorb the evidence from five decades of clinical research, most of which is peer-reviewed and published.”

Chapelle is unfazed regarding other potential obstacles to realizing her team’s vision for Havn Life. “The amount of collective knowledge and the fact that we are all trailblazers that have worked in nascent industries such as cannabis, technology, and formulations is such an incredible benefit. We have an ability to look at obstacles as challenges to be solved.” With the partnership with the University of British Columbia firmly in place and a diverse team of dedicated professionals, Havn Life’s mission appears anything but impossible. “Civilization has been enjoying mushrooms in both cultural ceremonies and for recreational purposes for eternity,” Chapelle asserts. “Access to a safe, properly dosed, standardized drug supply is long overdue.”

 


Don't Miss This Week's Exclusive News

Our team will cultivate the cannabis industry’s critical news and deliver it directly to your inbox every Friday. Don't miss it. Subscribe Now.

We respect your privacy. See our privacy policy.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 2 hours

Rise & shine. It’s Merger Mania in the industry this beautiful $HEXO $CURLF @Curaleaf_Inc…

@GreenMarketRpt – 2 hours

$CCHWF They missed, but only by a smidge and the quarter was really solid. #Cannabisstocks…

Back to Top